Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.
Our Forums moderator Kevin Schaefer published his list of entertainment options, perfect for these odd times we’re facing. To discuss, add more recommendations and leave your feedback please join the ... Read more
Isis Pharmaceuticals recently announced it received $2.15 million from Biogen to advance CHERISH, the ongoing pivotal Phase 3 study assessing ISIS-SMNRx in children suffering with spinal muscular atrophy (SMA). Isis has now received over $120 million from Biogen to advance ... Read more
Isis Pharmaceuticals, Inc. recently revealed its latest data on the Phase 2, open-label and multiple-dose study of ISIS-SMNRx in children diagnosed with spinal muscular atrophy (SMA) who are still receiving treatment in an open-label extension (OLE) ... Read more
Francesco Lotti, PhD from Columbia University was recently awarded $140,000 in funding from Cure SMA to support the researcher’s current project, entitled “Role of Sumoylation in SMN Function and SMA Pathology.” SMN, which stands for “survival ... Read more
Dr. Barrington G. Burnett was named the recipient of the 2014 Emerging Investigator $62,500 Finalist Award, according to a recent Gwendolyn Strong Foundation and FightSMA announcement. Dr. Barrington G. Burnett’s project was entitled “Targeting ... Read more
AveXis, Inc., a drug development company currently using gene therapy to address patients’ unmet needs suffering with orphan diseases such as Spinal Muscular Atrophy (SMA), has recently announced the completion of ... Read more
Orphan drug development company AveXis Inc. recently announced the completion of the dosing phase in the low-dose cohort of the company’s ongoing clinical trial efforts for its experimental Type 1 spinal muscular atrophy (SMA) therapy. ... Read more